Moderna (MRNA)
(Real Time Quote from BATS)
$57.44 USD
+0.13 (0.23%)
Updated Oct 16, 2024 03:53 PM ET
After-Market: $57.45 +0.01 (0.02%) 4:14 PM ET
4-Sell of 5 4
F Value B Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$57.44 USD
+0.13 (0.23%)
Updated Oct 16, 2024 03:53 PM ET
After-Market: $57.45 +0.01 (0.02%) 4:14 PM ET
4-Sell of 5 4
F Value B Growth D Momentum F VGM
Zacks News
The Zacks Analyst Blog Highlights: Regeneron, Moderna, Minerva Neurosciences, Amgen and Biogen
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Regeneron, Moderna, Minerva Neurosciences, Amgen and Biogen
Biotech Stock Roundup: REGN's Q1 Earnings Update, MRNA's Vaccine Data & More
by Zacks Equity Research
The biotech sector was in focus last week with earnings updates from Regeneron (REGN) and Moderna (MRNA) and regulatory updates from Amgen, among others.
Biotech ETFs to Suffer as US Backs IP Waiver for COVID-19 Vaccines
by Sweta Jaiswal, FRM
The Biden administration recently informed about supporting the waiver of intellectual property protections for COVID-19 vaccines that has been proposed by South Africa and India.
Moderna (MRNA) Beats on Q1 Earnings, Ups Vaccine Sales View
by Zacks Equity Research
Moderna (MRNA) reports first profitable quarter on the back of its success with COVID-19 vaccine. The number of COVID-19 vaccine doses delivered in the first quarter add up to 102 million.
Stock Market News for May 7, 2021
by Zacks Equity Research
Wall Street closed sharply higher on Thursday following strong labor market Data.
Will Moderna (MRNA) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Moderna (MRNA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Has Moderna (MRNA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (MRNA) Outperforming Other Medical Stocks This Year?
Moderna (MRNA) Beats Q1 Earnings Estimates
by Zacks Equity Research
Moderna (MRNA) delivered earnings and revenue surprises of 39.22% and -1.55%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $162.84 in the latest trading session, marking a -6.19% move from the prior day.
Google, Travelzoo, Moderna, Merck and Milestone Pharmaceuticals highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Google, Travelzoo, Moderna, Merck and Milestone Pharmaceuticals highlighted as Zacks Bull and Bear of the Day
Wall Street Gears for a Hectic Earnings Week
by Zacks Equity Research
Wall Street Gears for a Hectic Earnings Week.
Will Central Banks Start to Care About Fundamentals?
by John Blank
Macro-data has been much stronger than expected.¿¿¿¿¿¿ Still, the only thing that matters is NOT whether stock traders (or pundits) take note of strong data. It is whether the Fed and other major central banks care.
Markets Up to Start Another Busy Week
by Mark Vickery
With Q1 earnings season continuing to unfold favorably (for the most part), investors look to enjoy a healthy Q2, as well.
Moderna (MRNA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors are likely to focus on any updated outlook for Modena's (MRNA) authorized coronavirus vaccine and developmental progress with new COVID-19 vaccine candidate on the first-quarter earrings call.
Best Biotech Stocks & ETFs for mRNA, Gene Editing
by Neena Mishra
Here is what you should know about investing in these life changing technologies.
Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $175.67 in the latest trading session, marking a -1.68% move from the prior day.
Moderna (MRNA) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: NVIDIA, Booking Holdings, Altria Group, Moderna and Phillips 66
by Zacks Equity Research
The Zacks Analyst Blog Highlights: NVIDIA, Booking Holdings, Altria Group, Moderna and Phillips 66
Is First Trust Multi Cap Growth AlphaDEX ETF (FAD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FAD
Top Analyst Reports for NVIDIA, Booking Holdings & Altria
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA (NVDA), Booking Holdings (BKNG), and Altria Group (MO).
Moderna (MRNA) Stock Moves -0.83%: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $168.10, marking a -0.83% move from the previous day.
Ocugen (OCGN) Up on Positive Data for COVID-19 Vaccine Candidate
by Zacks Equity Research
Ocugen (OCGN) gains as partner Bharat Biotech shared positive results of the second interim analysis of its phase III study of COVAXIN.
J&J (JNJ) Gets Usage Guidance for COVID-19 Vaccine in Europe
by Zacks Equity Research
J&J (JNJ) is set to resume shipments of its COVID-19 vaccine to European countries, following positive recommendation from EMA's Pharmacovigilance Risk Assessment Committee (PRAC).
Emergent (EBS) Bayview Unit Operation on Hold for FDA Probe
by Zacks Equity Research
Emergent (EBS) halts manufacturing at Bayview facility as the FDA initiates investigation of the error that led to manufacturing of faulty doses of J&J's COVID-19 vaccine.
Bristol Myers (BMY) Opdivo Gets FDA Nod for Gastric Cancer
by Zacks Equity Research
Bristol Myers (BMY) obtains FDA approval for Opdivo in combination with chemotherapy for patients with gastric cancer, among others.